A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)
21 april 2020 uppdaterad av: Galderma R&D
A Multi-center Randomized, Double-blind, Placebo Controlled, Parallel-group Study of CD07743 for the Improvement of Lateral Canthal Lines (Crow's Feet)
This double-blind study has two parts for each subject (same population):
Part A: initial treatment in Lateral Canthal Lines (LCL) (placebo-controlled):
- To assess the efficacy and safety of Azzalure® compared to placebo in the improvement of moderate to severe LCLs.
- To assess the subjects' level of satisfaction with the appearance of their LCLs compared to placebo.
Part B: repeated treatment in LCL with or without Glabellar Lines (GL) (active treatment, up to 1 year):
- To assess safety of Azzalure® following repeated administration in the improvement of moderate to severe LCLs.
- To assess the safety of Azzalure® when used concomitantly for improvement of moderate to severe LCLs and GLs.
- To assess the subjects' level of satisfaction with the appearance of their LCLs.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
335
Fas
- Fas 3
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 65 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Male or female subjects, 18 to 65 years of age (Screening visit),
- Moderate or severe (grade 2 or 3, Hund 2006) Lateral Canthal Lines "at maximum smile" determined by investigator at screening and baseline
- Mild to severe (grade 1, 2 or 3, Hund 2006) Lateral Canthal Lines "at rest" determined by investigator at screening and baseline
- The subject is a female of childbearing potential and has a negative urine pregnancy test (UPT) at screening and baseline
- Subjects who are not satisfied with their appearance at screening and baseline
- The subject is willing and able to comply with the requirements of the protocol and agree to adhere to the visit schedule, concomitant therapy prohibitions and must be compliant to the study instruction.
- The subject agrees to participate in the study, verified by dating and signing an approved written Informed Consent Form (ICF) and Photography Consent Form (PCF) (selected sites only if applicable) at the enrolment visit before any study procedures at screening
Exclusion Criteria:
- Any prior surgery affecting the orbicularis oculi muscle, prior blepharoplasty or brow lift, or any prior cosmetic procedures or scars that may interfere with the evaluation of the investigator.
- Previous insertion of any permanent, semi-permanent or biodegradable material in the periorbital region or facial treatment with augmentation material (e.g. silicon injections, collagen type implants, hyaluronic acid, lactic acid, etc.) within 12 months prior to screening.
- Any prior treatment with botulinum toxin (of any serotype)
- Previous treatment with lasers for skin resurfacing (e.g. CO2 (carbon dioxide)-laser) or treatment with deep chemical peels and any other esthetic or dermatologic treatments or procedures in any area of the face within 12 months prior to screening.
- Any planned facial cosmetic surgery or procedures during the study period.
- Presence of any bleeding disorders
- Pregnant or lactating women or women who are planning pregnancy during the study.
- Known hypersensitivity to any of the test materials or related compounds.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Botulinum Toxin type A
During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
|
During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
|
|
Placebo-jämförare: Placebo
During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Responders on the Severity of Lateral Canthal Lines "at Maximum Smile".
Tidsram: Week 4
|
A positive response (responder) is defined as a grade of 0 or 1 (none or mild), as assessed by the investigator.
|
Week 4
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Participants Satisfied With the Appearance of Their Lateral Canthal Lines
Tidsram: Week 4
|
Participants were asked to assess their degree of satisfaction with the appearance of their lateral canthal lines using a 4-point scale with the grades Very satisfied, Satisfied, Dissatisfied, and Very dissatisfied.
A participant is considered satisfied if he/she answers Very satisfied or Satisfied.
|
Week 4
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 januari 2011
Primärt slutförande (Faktisk)
1 maj 2012
Avslutad studie (Faktisk)
1 maj 2012
Studieregistreringsdatum
Först inskickad
2 mars 2011
Först inskickad som uppfyllde QC-kriterierna
2 mars 2011
Första postat (Uppskatta)
3 mars 2011
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
1 maj 2020
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
21 april 2020
Senast verifierad
1 augusti 2012
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RD.03.SPR.40131
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .